Evaluation of vaginal atrophy symptoms and sexual function in Breast Cancer Survivors after local treatment with Radiofrequency
Not Applicable
- Conditions
- Sexual Dysfunction, PhysiologicalBreast NeoplasmsC12.050.351.500.894.906.316
- Registration Number
- RBR-2ntr3yd
- Lead Sponsor
- niversidade Federal do Rio Grande do Norte
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Women with nonmetastatic breast cancer; age 45 to 65 years; sexually active; with genitourinary symptoms
Exclusion Criteria
Women with recurrent or metastatic cancer; prior reconstructive pelvic surgery for prolapse; use any form of hormonal therapy in the last six months; use of lubricants or moisturizers in the past month; the presence of genital infections
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in the parameters of sexual function and quality of life is expected within a year, verified through updated and validated tests in Portuguese of the Female Sexual Function Index (FSFI) and a Short version of an instrument that evaluates the physical and mental health (A Short Form Health Survey SF-12), based on the verification of a variation of at least 30% in the pre-and post-intervention sessions.<br>
- Secondary Outcome Measures
Name Time Method Improvement in the parameters of vaginal atrophy (vaginal pain, burning, itching, dryness, dyspareunia, and dysuria) is expected within one year, verified using the 10-point Visual Analog Scale (VAS); Vaginal Health (epithelial integrity, vaginal elasticity, humidity, fluid volume, and vaginal pH), using the Vaginal Health Index (VHI), based on the verification of a variation of at least 30% in pre- and post-intervention measurements.